Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Chemomab Therapeutics Ltd. Market Cap
The Chemomab Therapeutics Ltd. (CMMB) share price is expected to increase by 351.98% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered CMMB. Price targets range from $4 at the low end to $11 at the high end. The current analyst consensus for CMMB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Chemomab Therapeutics Ltd. has a total of 3 Wall St Analyst ratings. There are 3 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Chemomab Therapeutics Ltd. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CMMB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jeff Jones Oppenheimer | Outperform | $11 | Reiterates | Nov 15, 2024 |
| Michael Okunewitch Maxim Group | Buy | $4 | Initiates | May 13, 2024 |
| Jeff Jones Oppenheimer | Outperform | $6 | Upgrade | May 6, 2024 |
| Jeff Jones Oppenheimer | Perform | Maintains | Mar 8, 2024 | |
| Dylan Dupuis Roth MKM | Buy | $7 | Reinstates | Dec 19, 2023 |
| Dylan Dupuis Roth MKM | Buy | $7 | Initiates | Oct 6, 2023 |
| Jeff Jones Oppenheimer | Perform | Downgrade | Jun 7, 2023 | |
| Jeff Jones Oppenheimer | Outperform | $7 | Maintains | Apr 18, 2023 |
| Jeff Jones Oppenheimer | Outperform | $20 | Maintains | Mar 10, 2022 |
Aegis Capital | Buy | Initiates | Dec 7, 2021 | |
Cantor Fitzgerald | Overweight | Initiates | May 26, 2021 | |
Oppenheimer | Outperform | Initiates | May 7, 2021 |
When did it IPO
2019
Staff Count
0
Country
Israel
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Adi Mor George Ph.D.
Market Cap
$31.9M
In 2023, CMMB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CMMB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Chemomab Therapeutics will participate in Oppenheimer's Movers in Rare Disease Summit on December 12, 2024, highlighting potential stock-moving catalysts for investors.
Why It Matters - Chemomab's participation in the Rare Disease Summit highlights potential catalysts that could influence stock performance, attracting investor interest in the biotech sector.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Chemomab's CM-101 shows broad clinical activity and potential disease modification in primary sclerosing cholangitis (PSC), according to an AASLD presentation.
Why It Matters - Chemomab's CM-101 showing broad clinical activity and disease-modifying potential in PSC may indicate strong future growth and market potential, influencing investor sentiment and stock performance.
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Chemomab Therapeutics (NASDAQ: CMMB) reported Q2 2024 earnings per share of -26 cents.
Why It Matters - Chemomab's Q2 2024 earnings of -26 cents per share indicate ongoing losses, which may affect investor confidence and stock performance.
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CM-101 advances to Phase 3 after positive Phase 2 PSC data. New financing secures cash until early 2026, with two milestones expected in Q1 2025.
Why It Matters - Positive Phase 2 results for CM-101 boost confidence in its potential, while extended financing ensures operational stability through early 2026, supporting growth and upcoming milestones.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Chemomab Therapeutics Ltd. will release its Q2 2024 financial results and a business update on August 21, 2024, at 7:00 am ET, as it develops therapeutics for fibro-inflammatory diseases.
Why It Matters - Chemomab's upcoming financial results and business update could impact stock performance, indicating progress in their drug development and influencing investor sentiment.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Chemomab secured $10 million in PIPE financing, involving both new and existing investors, extending its cash runway until early 2026.
Why It Matters - Chemomab's $10 million PIPE financing enhances liquidity and investor confidence, extending operational capacity into 2026, which may positively impact future growth and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
